(Alliance News) - Physiomics PLC on Tuesday said it has secured a new contract with long-standing client Numab Therapeutics AG, a Swiss clinical stage biotech company focused on the development of multi-specific antibodies in immunology and oncology. Read More
Physiomics PLC - Oxfordshire, England-based mathematical modelling company that supports oncology drug development - Secures contract worth GBP102,000 with a new UK-based biotech firm that is focused on developing antibody drug conjugates based therapies targeting difficult-to-treat cancers. Says the contract will see it develop a pharmacokinetic pharmacodynamic model to inform optimal dosing for the client's upcoming first-in-human trial. Expects the project to run from April until August this year. Chief Executive Peter Sargent says: "We are delighted to be awarded this contract. Not only is this contract with a brand new client, but is also in the area of ADCs; a hot new area of oncology treatments." Read More
Physiomics PLC - Oxfordshire, England-based mathematical modelling company that supports oncology drug development - Pretax loss widens to GBP249,000 in the six months to December 31 compared with GBP235,000 a year prior as revenue dips 12% to GBP329,000 from GBP374,000. Highlights strong pipeline with four contracts won in the first half of the financial year. Based on these signed contracts, the company expects total income for the current financial year will be in line with market expectations, with additional contracted revenue projected into next year - year to June 2026. The company is "actively progressing" a number of late-stage opportunities, however, there is no guarantee that these contracts will be signed within the current financial year. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Physiomics PLC on Wednesday said its personalised dosing software project has now obtained the key approvals needed to progress with its observational trial. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - Physiomics PLC on Tuesday said that it has been awarded a new contract by an existing, large pharmaceutical client. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
Physiomics PLC - Abingdon, Oxfordshire-based mathematical modelling and data science for new medicines - Wins new contract from "an existing, large client", worth GBP186,000. According to the agreement, the client will use Physiomics' proprietary Virtual Tumour platform to model its targeted oncology agents in combination with other modalities, in order to help inform dose and scheduling decisions. As a result, Physiomics will be entering the next financial year - ending June 30, 2025 - with committed revenue of over GBP500,000. Read More
Physiomics PLC - Abingdon, Oxfordshire-based mathematical modelling and data science for new medicines - Says it has been awarded a significant contract by a new UK-based biotech client, which it left unnamed. "This client sits at the forefront of AI-driven design and development of novel therapies across various therapeutic areas," the company says. The project involves the use of Physiomics' Virtual Tumour technology to help guide the phase 1b/2 dosing regimens for one of their oncology assets and benchmark it against the competition. The project is valued at GBP161,580 and is anticipated to be completed over the next five months. Read More
(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and Friday this week and not separately reported by Alliance News: Read More
Physiomics PLC - Milton Park, England-based data science company, focused on new therapeutics and personalised medicine solutions - Warns several large contracts have taken longer than expected to be signed. It predicts total income for the year to June 30 will decline to a range of GBP600,000-GBP650,000 as a result. It adds: "The company is in the final stages of negotiation for two projects (one with an existing client and one with a potential new client), the total value of which is expected to be, in aggregate, approximately GBP350,000. Whilst the board anticipates that the contracts for these two projects will be signed in FY24, the majority of the revenue is now expected be recognised in the company's next financial year ending 30 June 2025, and accordingly the board's expectations for FY25 revenues have been correspondingly increased." Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More
Physiomics PLC - mathematical modelling company that supports oncology drug development - Receives a "substantial" new contract by an existing "large pharma" client, though doesn't specify whom the client is. The project, which is valued at GBP178,000, involves involves pharmacokinetic-pharmacodynamic modelling in the field of DNA damage and repair fields. It is designed to help inform clinical dose and scheduling decisions. Physiomics expects this work to be completed over the course of the next six months. Read More
(Alliance News) - Physiomics PLC on Thursday reported higher interim revenue and a narrowed loss. Read More